Stephen James Farr

US Patent:

6427681, Aug 6, 2002

Filed:

Jun 21, 2001

Appl. No.:

09/888094

Inventors:

Igor Gonda - San Francisco CA
Reid M. Rubsamen - Oakland CA
Stephen J. Farr - Orinda CA

Assignee:

Aradigm Corporation - Hayward CA

International Classification:

A61M 1100

US Classification:

12820014, 12820022, 12820423

Abstract:

The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patients breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.

US Patent:

6431166, Aug 13, 2002

Filed:

Feb 15, 2001

Appl. No.:

09/784861

Inventors:

Igor Gonda - San Francisco CA
Reid M Rubsamen - Oakland CA
Stephen J. Farr - Orinda CA

Assignee:

Aradigm Corporation - Hayward CA

International Classification:

A61M 1100

US Classification:

12820014, 12820022, 12820423

Abstract:

The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patients breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.

US Patent:

6431167, Aug 13, 2002

Filed:

Oct 9, 2001

Appl. No.:

09/975085

Inventors:

Igor Gonda - San Francisco CA
Reid M. Rubsamen - Oakland CA
Stephen J. Farr - Orinda CA

Assignee:

Aradigm Corporation - Hayward CA

International Classification:

A61M 1100

US Classification:

12820014, 12820022, 12820423

Abstract:

The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patients breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.

US Patent:

6688304, Feb 10, 2004

Filed:

Sep 10, 2001

Appl. No.:

09/950562

Inventors:

Igor Gonda - San Francisco CA
Reid M. Rubsamen - Alamo CA
Stephen J. Farr - Orinda CA

Assignee:

Aradigm Corporation - Hayward CA

International Classification:

A61M 1100

US Classification:

12820014, 12820022, 12820312, 12820423

Abstract:

Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.

US Patent:

6799576, Oct 5, 2004

Filed:

May 15, 2002

Appl. No.:

10/147390

Inventors:

Stephen J. Farr - Orinda CA

Assignee:

Aradigm Corporation - Hayward CA

International Classification:

A61M 1600

US Classification:

131271, 131270, 131328, 12820014, 12820012

Abstract:

A system is disclosed which makes it possible for a patient to be delivered gradually reduced amounts of nicotine over time thereby allowing the patient to be gradually weaned off of dependence on nicotine and quit smoking. The system is comprised of a means for aerosolizing a formulation and containers of formulation. The formulation is comprised of nicotine in a pharmaceutically acceptable carrier. Preferably, a plurality of containers are produced wherein the concentration of nicotine in the different containers or different groups of containers is reduced. The patient uses containers with the highest concentration initially and gradually moves towards using containers with lower and lower concentrations of nicotine until the patients dependence on nicotine is eliminated.

US Patent:

6874507, Apr 5, 2005

Filed:

Aug 6, 2004

Appl. No.:

10/913103

Inventors:

Stephen J. Farr - Orinda CA, US

Assignee:

Aradigm Corporation - Hayward CA

International Classification:

A16M016/00

US Classification:

131271, 131270, 131328, 12820014, 12820012

Abstract:

A system is disclosed which makes it possible for a patient to be delivered gradually reduced amounts of nicotine over time thereby allowing the patient to be gradually weaned off of dependence on nicotine and quit smoking. The system is comprised of a means for aerosolizing a formulation and containers of formulation. The formulation is comprised of nicotine in a pharmaceutically acceptable carrier. Preferably, a plurality of containers are produced wherein the concentration of nicotine in the different containers or different groups of containers is reduced. The patient uses containers with the highest concentration initially and gradually moves towards using containers with lower and lower concentrations of nicotine until the patient's dependence on nicotine is eliminated.

US Patent:

7021309, Apr 4, 2006

Filed:

Oct 8, 2003

Appl. No.:

10/682529

Inventors:

Igor Gonda - Melbourne, AU
Reid M. Rubsamen - Alamo CA, US
Stephen J. Farr - Orinda CA, US

Assignee:

Aradigm Corporation - Hayward CA

International Classification:

A61M 11/00

US Classification:

12820014, 12820312, 12820423

Abstract:

The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.

US Patent:

7028686, Apr 18, 2006

Filed:

Nov 4, 2003

Appl. No.:

10/701967

Inventors:

Igor Gonda - San Francisco CA, US
Reid M. Rubsamen - Oakland CA, US
Stephen J. Farr - Orinda CA, US

Assignee:

Aradigm Corporation - Hayward CA

International Classification:

A61M 11/00

US Classification:

12820014, 12820022, 12820312, 12820423

Abstract:

Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.